Abbott hits the sweet spot, pays $110M cash for PhIIb drug

Still wheeling and dealing on the road up to its spinoff this year, the drug arm of Abbott Laboratories ($ABT) has snagged Action Pharma's Phase IIb program for acute kidney injury with a one-time pay…
Read the full story: News